Health Canada has recently approved a NEW indication for Trelegy® Ellipta® for the treatment of asthma in adults 18 years and older, and for a new strength (200/62.5/25 mcg) to allow flexibility in dosing of asthma patients. For more information please read the product monograph for Trelegy® Ellipta®.
Lung Sask in collaboration with RESPTREC® offers the Professional Education Portal as a method for respiratory educators and health care providers to enhance their professional learning with continuing education opportunities.
Over 6000+ more articles available in the Professional Education Portal.
Read articles and watch video presentations on the most recent research, position papers and guidelines. Track your CE time with the provided logbook.